Beth Manchester Promoted COO at InfoWerks

Beth Manchester has been promoted to Chief Operations Officer of InfoWerks Data Services LLC, a leading provider of healthcare data services.

Having paved a highly successful and tenured career of over two decades, Beth’s rise to the Executive Leadership Team will help shape the direction of InfoWerks and influence the vision of the healthcare data industry.

Beth Manchester has over 20 years of experience leading teams and complex projects for Transaction Data Systems (TDS), one of the most prominent healthcare data companies in the industry. Before joining the team at InfoWerks, she was responsible for driving adoption of one of the most popular pharmacy management platforms, Rx30, from roughly 800 pharmacies to over 8,500 by the time of her departure. Beth also served in other managerial and director-level roles during her tenure.

“If there’s anybody who knows pharmacy data, it’s Beth,” said Jeff Deitch, Chief Executive Officer of InfoWerks. “She’s been involved with large-scale data conversions, coordinated new system installations across the country, and overseen acquisitions. Her technical prowess and intuition are unparalleled; we are extremely lucky to have her on our team.”

“Thanks to Beth, TDS has become one of our best partners,” said Paul Placek, Chief Relationship Officer of InfoWerks. “We’ve done thousands of projects together over the years and look forward to thousands more. She has earned this position in every respect.”

Moving forward, Beth will be focused on maximizing operational efficiencies and customer satisfaction, as well as striving for alignment among all internal and external teams. Her appointment marks the beginning of the next chapter for InfoWerks, with a focus on expanding into new verticals within the healthcare data space.

Hot this week

Recor Medical Supports European Society of Cardiology’s Hypertension Guidelines

Record Medical notes the new guidelines, "2024 ESC Guidelines for the management of elevated blood pressure and hypertension," have been published online and recommend the consideration of renal denervation (RDN) as a safe and effective treatment option for patients who have uncontrolled resistant hypertension or those that have uncontrolled hypertension with a higher risk of cardiovascular disease, who express a preference to undergo RDN.

ConTIPI Medical Selects EVERSANA to Support U.S. Commercialization of Non-Surgical Medical Device ProVate for Women with Pelvic Organ Prolapse

EVERSANA is a leading provider of global commercial services to the life sciences industry, to support commercialization for the ProVate device in the United States to help women experiencing pelvic organ prolapse.

Boston Scientific Obtains CE Mark for ACURATE Prime Aortic Valve System

The ACURATE Prime aortic valve system is designed with several features to build upon the clinical performance of the ACURATE neo2™ platform including an additional valve size, which expands the treatment range to patients with a larger anatomy.

Noctrix Health Announces New CMS Reimbursement Codes and Payment for Nidra Tonic Motor Activation Therapy for Restless Legs Syndrome

Nidra TOMAC Tonic Motor Activation Therapy, which was authorized for marketing in the United States last year following its designation as a "Breakthrough Device" by the US Food & Drug Administration (FDA), remains the only clinically validated, non-pharmaceutical treatment available for patients with RLS.

Haemonetics Announces Full Market Release for VASCADE MVP® XL Vascular Closure System

Haemonetics notes the VASCADE MVP XL system is now available to U.S. hospitals as the newest addition to Haemonetics' VASCADE® portfolio of vascular closure systems featuring an innovative collapsible disc technology and a proprietary resorbable collagen patch designed to promote rapid hemostasis.